Aadi Bioscience Files Proxy Materials
Ticker: WHWK · Form: DEFA14A · Filed: Feb 18, 2025 · CIK: 1422142
Sentiment: neutral
Topics: proxy, filing, corporate-governance
Related Tickers: AADI
TL;DR
AADI proxy filing dropped. Shareholders getting the scoop.
AI Summary
Aadi Bioscience, Inc. filed a Definitive Additional Materials proxy statement on February 18, 2025. This filing relates to the company's proxy materials, which are being provided to shareholders. The company was formerly known as Aerpio Pharmaceuticals, Inc. and Zeta Acquisition Corp II.
Why It Matters
This filing indicates that Aadi Bioscience is engaging with its shareholders regarding important company matters, likely related to upcoming votes or corporate governance decisions.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not contain new financial information or strategic changes that would inherently increase risk.
Key Players & Entities
- Aadi Bioscience, Inc. (company) — Registrant
- Aerpio Pharmaceuticals, Inc. (company) — Former company name
- ZETA ACQUISITION CORP II (company) — Former company name
- 20250218 (date) — Filing date
FAQ
What type of filing is this?
This is a DEFA14A filing, specifically Definitive Additional Materials, filed by Aadi Bioscience, Inc.
When was this filing submitted?
The filing was submitted on February 18, 2025.
What is the company's Central Index Key (CIK)?
Aadi Bioscience, Inc.'s Central Index Key is 0001422142.
What were the company's previous names?
The company was formerly known as Aerpio Pharmaceuticals, Inc. and Zeta Acquisition Corp II.
What is the company's primary business sector?
Aadi Bioscience, Inc. is in the Pharmaceutical Preparations sector, with SIC code 2834.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on February 18, 2025 regarding Aadi Bioscience, Inc. (WHWK).